Azole Antifungal

PreclinicalSmall molecule

Azole Antifungal is one of 18 small molecule programs targeting Vulvovaginal Candidiasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vulvovaginal CandidiasisActive, not recruiting

Vulvovaginal CandidiasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Vulvovaginal Candidiasis

#DrugCompanyPhaseTrials

Lotrimin

Bayer

Approved

4 2

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

15 3

Nizoral

Terazol 3

2 5

Canesten

AAVVA Pharmaceuticals Ltd.

Approved

1 6

Peridex

MMedline Industries

Phase 2

1 7

Vaccine

Pfizer

Phase 2

1 8

Brexafemme

GGlaxo Dba Glaxosmithkline

Phase 3

4 9

Boric Acid

MMansoura University

Phase 3

1 10

Butoconazole Nitrate

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vulvovaginal Candidiasis1 trial

Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis

Completed·—·N/A·NCT05795491·60 enrolled

Resistance1 trial

Efflux Pump Mediated Azole Resistance in Candida Albicans

Unknown status·—··NCT03659162·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Azole Antifungal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azole Antifungal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azole Antifungal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assiut University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAssiut University

Azole Antifungal

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vulvovaginal Candidiasis1 trial

Resistance1 trial

References

Drug Info

Quick Facts

Related News